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Abstract
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Background—The glycation of human serum albumin (HSA) during diabetes can affect the
ability of this protein to bind drugs and small solutes in blood. This study describes the use
of 16O/18O-labeling and matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry to compare the levels of modification that occur throughout HSA under various
glycation conditions in vitro. These quantitative studies build on a recent report that has identified
the early and advanced glycation products that are formed on such samples of HSA.
Methods—Glycated HSA samples were prepared by incubating 42 g/l HSA with 0 to 15 mmol/l
glucose at pH 7.4 and 37°C for up to 5 weeks. A control HSA sample was digested in 16Oenriched water and glycated HSA samples were digested in the presence of 18O-enriched water.
These 2 types of samples were then mixed and the amounts of 16O- vs. 18O-labeled peptides were
measured to determine the levels of modification that were occurring throughout HSA.
Results—The largest levels of modification occurred in residues 101-119, 1-10 or 42-51, 87-100,
360-372, 521-531, and 275-286 of HSA after 2 weeks of glycation, and in residues 21-41, 1-10 or
42-51, 521-531, 82-93, and 146-160 after 5 weeks of glycation. Some of these regions contained
the N-terminus, K199, K439, and K525, which have been previously identified as major glycation
sites on HSA. The glycation pattern of HSA was dominated by early glycation products (e.g.,
fructosyl-lysine) after a reaction period of 2 weeks for mildly glycated HSA, while advanced
glycation end products became more prominent at longer reaction times.
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Conclusions—The time course of the observed modifications indicated that the pattern of
glycation products changed as HSA was incubated over longer periods of time with glucose.
Several regions found to have significant levels of modification were at or near the major drug
binding regions on HSA. These results explain why the interaction of some drugs with HSA has
been observed to vary with the level of glycation for this protein.
Keywords
Non-enzymatic glycation; Human serum albumin; Diabetes; Matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry; 16O/18O-Labeling; Quantitative proteomics
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The non-enzymatic glycation of various proteins in the body has been linked to many of the
chronic complications of diabetes, including nephropathy, macrovascular problems, and
cataract formation [1-4]. These reactions and processes are typically accelerated during
diabetes because of the increased blood sugar concentrations found in this disease [4,5]. The
early stages of glycation involve the reaction of a reducing sugar, such as glucose, with
primary amine groups on a protein [6-8]. This reaction leads to the formation of a Schiff
base, which can later rearrange to form a more stable Amadori product (see Figure 1) [9,10].
Over time, reactive dicarbonyl compounds can form through the degradation of glucose or
other free sugars (e.g., via retroaldol condensation and auto-oxidation) [11,12] and can
combine with arginine or lysine residues on proteins to form advanced glycation end
products (AGEs). Some AGEs can also form through the oxidation and rearrangement of
Amadori products [13].
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It has been proposed that glycation-related modifications of human serum albumin (HSA),
the main protein in serum, can alter the binding of this protein with drugs and small solutes
[14-18]. HSA is the major carrier protein for many drugs and hormones in the circulation
[19], which makes studies of HSA glycation of great potential interest in understanding how
the role of this protein as a binding and transporting agent may be altered during diabetes. A
few previous studies have been conducted to determine the levels of modification that occur
at various regions on glycated HSA, but most of these reports have only looked at specific
modifications such fructosyl-lysine (FL) or some types of AGEs (e.g., those formed from
methylglyoxal) [19-22]. However, it is known there are actually many glycation-related
modifications that can occur on HSA [19,20,22]. It has also been found that different levels
of glycation can alter the binding properties of this protein [14,22-24]. These results indicate
that there is a need for a better understanding of how the degree and types of glycationrelated modifications on HSA may change as the extent of glycation for this protein is varied
[1,20].
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The purpose of this study is to quantitatively examine the modification patterns that occur
for in vitro glycated HSA at various overall levels of glycation. These patterns will be
examined by using 16O/18O-labeling and matrix-assisted laser desorption/ionization time-offlight mass spectrometry (MALDI-TOF MS). To analyze the glycation patterns, a control
digest of HSA will be made in the presence of an 16O-enriched buffer, while similar digests
of glycated HSA samples will be prepared in an 18O-enriched buffer (Fig. 2) [25-27]. These
samples will then be mixed and the 16O/18O ratios for the peptides in each digest sample
versus the control will be determined by using MALDI-TOF MS. The use of 18O-labeling in
mass spectrometry has been shown to be highly sensitive to changes in peptide
concentration, with detection limits in the femtomol range having been reported in Ref. [28].
MALDI-TOF and 16O/18O-labeling has previously been used to rank modification sites in a
single, commercial sample of mildly glycated HSA [27] but has not yet been used to
compare multiple samples of glycated HSA.
In this current study, 16O/18O-labeling and MALDI-TOF MS will be used to determine
which regions on HSA have undergone a change in their level of modification during
glycation and to examine these changes as a function of reaction time or glycation
conditions. A recent report has used qualitative peptide mass fingerprinting to examine the
same glycated HSA samples that will be examined in this current study [29]; this earlier
report found that several residues on glycated HSA can contain early or advanced glycation
products (e.g., lysine 93, 199, 276, 281, 286,414, 439 or 524/525, and arginine 98, 197 or
521). It has also been observed in this prior work that some of these modifications occur at
or near the major drug binding regions on HSA [29]. This current study will expand on these
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findings by providing quantitative information on the relative degree of modification that
occurs at such regions of HSA and on how the pattern of these modifications can change
over the time allowed for glycation. This work will be carried out by using in vitro samples
of glycated HSA that are prepared under conditions mimicking those found in blood during
diabetes. The information generated in these experiments should be valuable in
understanding how changes in glycation may affect the ability of HSA to bind drugs and
small solutes during diabetes. The methods described in this report should also be useful for
the quantitative analysis and comparison of other proteins or protein modifications that are
of interest to clinical and biomedical research.

2. Materials and methods
2.1. Materials
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The following chemicals were purchased for Sigma-Aldrich (St. Louis, MO): desArgbradykinin (97% pure), glu-fibrinopeptide (97%), angiotensin I (97%, acetate salt), 2,3dihyroxybenzoic acid (98%), α-cyano-4-hydroxycinnamic acid (99%), HSA (99%,
essentially fatty acid and globulin free), trypsin (sequence grade), Glu-C (sequence grade),
Lys-C (sequence grade), D-glucose (99%), iodoacetamide (99%), trifluoroacetic acid (98%),
sodium azide (99%), formic acid (96%), molecular biology-grade water (DNase, RNase, and
protease free), methanol (HPLC-grade, 99.9%), 18O-enriched water (97%), 16O-enriched
water (99.99%), and acetonitrile (HPLC-grade, 99.9%). Unless indicated otherwise, all
water used for sample pretreatment and the preparation of solutions was obtained from a
Nanopure system (Barnstead, Dubuque, IA).
2.2. Apparatus
The siliconized low retention microcentrifuge tubes (0.6 ml and 1.5 ml) and 0.20 μm nylon
filters were obtained from Fisher Scientific (Pittsburgh, PA). Slide-A-Lyzer dialysis
cassettes (7000 Da MW cutoff, 0.1-0.5 ml and 0.5-3 ml) were from Pierce (Rockford, IL).
The μ-C18 ZipTip pipette tips (0.2 μl bed volume) were purchased from Millipore (Billerica,
MA). Mass spectra were collected on a Voyager 6148 MALDI-TOF MS system (Applied/
Perspective Biosystems, CA). The instrument settings were as follows: positive-ion delayed
extraction reflection mode; delay time, 100 ns; accelerating voltage, 25 kV; guide wire
voltage, 0.008% of accelerating voltage; grid voltage, 77% of accelerating voltage. Matlab
2009a, which included the bioinformatics toolbox, was obtained from Mathworks (Natick,
MA). Mascot Wizard was obtained from Matrix Science (London, UK) [30].
2.3. Preparation and digestion of glycated HSA
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The preparation of the glycated HSA has been described in detail in a previous report [29].
The HSA was dissolved at a concentration of 42 g/l (or 0.63 mmol/l) in pH 7.4, 0.2 mol/l
potassium phosphate buffer. This buffer also contained 1 mmol/l sodium azide as a
preservative and prepared using molecular biology-grade water [31,32]. The initial
concentration of HSA was selected to mimic the level of HSA that is typically found in
serum (i.e., 35–50 g/l). Two initial solutions of HSA were prepared: the first solution
contained 15 mmol/l D-glucose (or 270 mg/dl), which represented a glucose concentration
that is typically found in blood during poorly-controlled diabetes [33]. The second HSA
solution was used as a control and did not contain glucose. The control solution was
incubated for 5 weeks at 37 °C. The HSA/glucose mixture was incubated under the same
conditions, with aliquots being removed after 2 weeks and 5 weeks. Following the
incubation step, the HSA was removed from the other solution components by using sizeexclusion chromatography and several cycles of dialysis against water. The purified HSA
was lyophilized and stored at 4 °C until later use. The glycation content of each HSA sample
was determined by using a modified fructosamine assay [29].
Clin Chim Acta. Author manuscript; available in PMC 2012 August 17.
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The pretreatment of HSA (i.e., denaturation, reduction, and alkylation) was performed
according to recent methods reported in the literature [27,29]. Following these pretreatment
steps, each HSA sample was placed into a 0.1–0.5 ml dialysis cassette. Dialysis was
performed on these samples versus three 1000 ml portions of water for 4 h each at room
temperature. The resulting control and glycated HSA solutions were adjusted to the same
volume. A 40 μl aliquot of each HSA solution was placed into several low retention
microcentrifuge tubes and these samples were dried under vacuum with no heating. The
vials, which now contained approximately 80 μg of either the control HSA or glycated HSA,
were stored at -80 °C until use. Digests of these samples were prepared using trypsin, Glu-C
and Lys-C, as described previously [27]. The digested samples were stored at -80 °C until
use.
2.4. MALDI-TOF MS
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The procedures used for preparing the MALDI matrix, calibrating the mass spectrometer,
and carrying out peptide fractionation for the various digests of HSA have been described in
detail elsewhere [27,29]. The MALDI matrix consisted of a mixture of 2,3-dihyroxybenzoic
acid and α-cyano-4-hydroxycinnamic acid. Glu-fibrinopeptide (1570.68 Da), des-Argbradykinin (904.47 Da), and angiotensin I (1296.68 Da) were used as external mass
calibrants. The HSA digests were fractionated using μ-C18 ZipTip pipette tips and step
gradients of 5, 10, 20, 30, or 50% acetonitrile in water [34-36]. The eluted peptides were
mixed with the MALDI matrix, spotted onto a MALDI plate, dried, and analyzed by
MALDI-TOF MS. Peptide mass mapping was performed with a maximum allowed mass
error of 50 ppm.
The 16O/18O ratio for a given peptide in a mixed digest was obtained from the MALDI-TOF
MS data by using Eqn. (1) [27,35].

(1)
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The terms I’ and I” in Eqn. (1) represent the contributions from the 16O- and 18O-labeled
components of the mixed digest, respectively. The subscripts 0, 2, and 4 in Eqn. (1) refer to
whether the given contribution comes from peptides that contained zero (M+0 peak), one (M
+2 peak), or 2 (M+4 peak) 18O-labels. These contributions were determined algebraically by
incorporating mass/area values from both the 16O- and 18O-labeled spectra, as described
earlier [27,35]. Unless stated otherwise, the measurement of the 16O/18O ratio for a given
peptide in a collected fraction from a digest was performed in triplicate, and the 16O/18O
ratios for the same peptide found in different fractions were combined and averaged. A
Student's t-test [37] was carried out at the 90% confidence level to identify peptides
with 16O/18O ratios in a test sample that were significantly higher than results for the same
peptides in the reference, control sample.

3. Results and discussion
3.1. Initial analysis of glycated HSA
The control HSA sample used in this study had only a small amount of glycation-related
modifications (i.e., less than 0.1 mol hexose per mol of HSA), as determined by a
fructosamine assay [29]. The glycated HSA samples that were prepared using 2 or 5 weeks
of incubation with 15 mmol/l glucose contained 0.7 (± 0.1) or 1.2 (± 0.1) mol hexose per
mol of HSA when measured by the same approach. These levels of glycation represent the
amount that is typically found in pre-diabetes (~0.5-1 mol hexose per mol HSA) or diabetes
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(1-15 mol hexose per mol HSA), respectively [38,39]. When combining the results for all
digests, these samples were found to have usable sequence coverages of 86%, 82%, and
86%, respectively, for the quantitative studies that are described in this report (see Figure 3).
The coverage obtained in this work was sufficient for the analysis of the N-terminus, all
arginines, and 84-85% of the lysine residues on HSA in all of the samples that were
examined. Analysis of the remaining 15-16% lysines in HSA was not required in this report
because these particular residues have been found in prior studies to not have any
measurable levels of glycation-related modifications [19-22].
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In the analysis method that was used in this study, the glycation or modification of a given
peptide should have led to a decrease in the amount of unmodified peptide and an increase
in the corresponding 16O/18O ratio for this region when comparing the control sample to a
glycated HSA sample. Figure 4 illustrates this approach by showing some typical mass
spectra that were obtained when there was an increase in the 16O/18O ratio for a peptide
containing residues 521-531 of HSA. This particular region of HSA contains K525, which is
a well-characterized glycation site on this protein [20]. Based on an analysis of the mass
spectrum in Figure 4(a) and through the use of Eqn. (1), the reference 16O/18O ratio for this
peptide in the original control sample was found to be 1.15 (± 0.13). When using the data in
Figure 4(b), the 16O/18O ratio increased to 1.80 (± 0.46) in the mildly glycated HSA sample
that was obtained after 2 weeks of incubation with glucose. An even larger increase in this
ratio to 2.00 (± 0.46) was found in the glycated HSA sample after 5 weeks of incubation
with glucose (data not shown). By using these ratios, it was possible to obtain a quantitative
measure of the relative degree to which this and other regions of HSA were affected by
glycation-related modifications at different incubation times with glucose.
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To make it easier to compare changes in the 16O/18O ratios for different peptides from the
glycated HSA samples versus normal HSA, a correction was also made for the small
variations that occurred in the degree of 16O- or 18O-labeling during the production of
peptide fragments from HSA. For instance, the 16O/18O ratios for peptides in the control
sample (i.e., as found by examining the control sample versus itself when prepared in 16Oenriched or 18O-enriched buffer) varied from 0.58–2.76, 0.50–3.37, and 0.17–2.12 for the
trypsin, Glu-C, and Lys-C digests, respectively. The variations seen in these values for the
control most likely reflect the differences in how the given enzymes interact with various
regions of HSA, as has been noted when using a similar approach to compare immobilized
HSA versus soluble HSA [35]. In this type of situation, a comparison of the 16O/18O ratio
for a test sample versus the same ratio for an appropriate control sample was found to be a
more effective route for comparing the amount of modification that was occurring at
different regions of HSA. This approach was employed in this study by
determining 16O/18O ratios for 1) each glycated HSA sample versus a control sample of
normal HSA and 2) the control HSA sample versus itself after digestion of this sample in
both 16O-enriched and 18O-enriched water. A value referred to here as the “glycated/control
index” was then determined for each peptide by dividing the 16O/18O ratio for that peptide
in the glycated HSA/control HSA mixture by the 16O/18O ratio for the same peptide in the
control HSA/control HSA mixture. The glycated/control index provided a normalized scale
in which all peptides in the original control sample had an initial reference index of one. An
index value greater than one was produced when a glycation-related modification occurred
in a given region of HSA, with the size of this index increasing as the amount of
modification increased. This feature made it possible with this index to better determine
which regions of HSA were most affected by glycation-related modifications and to
compare the time course of these processes, as will be discussed later.
Table 1 shows the 16O/18O ratios that were obtained for all of the peptides that were
examined in this work and the glycated/control index values that were calculated for the
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various regions on HSA from which these peptides originated. The standard error of the
mean for each 16O/18O ratio and for each calculated glycated/control index is also provided
in Table 1. Regions on HSA that had significant levels of modification were identified by
using a Student's t-test to compare the 16O/18O ratios for the control sample to the 16O/18O
ratios for the glycated HSA samples. Peptides from the glycated HSA samples that gave an
increase in the 16O/18O ratio versus the control sample at the 90% confidence level were
considered to represent significant levels of modification. The corresponding glycated/
control index values for these peptides were then used in further work to compare the levels
of modification that were measured for peptides from different regions of HSA.
3.2. Peptides with high 16O/18O ratios in mildly glycated HSA
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A detailed examination was first made of the results for the mildly glycated HSA that was
prepared using a 2 week incubation period with 15 mmol/l glucose. A total of 16 peptides in
this sample gave 16O/18O ratios that were significantly higher (at the 90% confidence level)
versus results for the same peptides in the control HSA sample. These peptides had a
relative increase of 6% to 77% in their glycated/control indices versus the control. Based on
these ratios, the largest amount of modification in the mildly glycated HSA sample was
found to occur at residues 101-119, 1-10 or 42-51, 87-100, 360-372, 521-531, and 275-286.
The peptides from these regions gave glycated/control indices that represented a relative
increase of 47-77% in the 16O/18O ratios for these residues in the mildly glycated HSA
versus the control sample. Smaller amounts of modification were found on residues
324-336, 414-428, 373-389, 241-257, 142-153, 154-167, 502-518, 426-442, 209-227, and
61-82 in the mildly glycated HSA, with glycated/control index values that represented an
increase of 16-31% in the 16O/18O ratios versus the control sample.
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The N-terminus, K525 and K281 are among the most common glycation sites that have been
reported for HSA [19,20,27,34,40]. In this study, these residues were found to occur in
peptides with glycated/control index values of 1.64, 1.57, and 1.47, respectively, for the
mildly glycated HSA. These residues are all located in regions that were found to have the
highest levels of modification in glycated HSA after 2 weeks of incubation with glucose. In
addition to these regions, a peptide corresponding to residues 426-442 was found to have an
elevated glycated/control index of 1.20 (± 0.07). The increase in the glycated/control index
at this latter region was lower than that seen for the glycated/control index of the more
commonly-identified modified regions in glycated HSA. However, this site is worth
mentioning because it has been previously identified as a likely modification site for in vivo
glycated HSA [20]. Residues 189-208 may also have had an elevated glycated/control index
(e.g., due to modification at K199, a known glycation site on HSA) [20,34], with a value of
1.25 (± 0.49) for the mildly glycated HSA sample. While the variation in this index and the
corresponding 16O/18O ratios meant that this increase was not significant at the 90%
confidence level, this region did have a significant increase in its glycation/control index for
the more highly glycated HSA that was produced after 5 weeks of incubation with glucose
(see next section).
The regions in the mildly glycated HSA sample that were found to contain significant
amounts of modification were compared to observations made in prior work with glycated
HSA. For instance, all of the regions found to have moderate-to-high levels of modification
in a previous report using a commercial in vitro preparation of minimally-glycated HSA [27]
were also found to have moderate-to-high levels of modification for the mildly glycated
HSA sample that was prepared and examined in this current study. These regions contained
residues R81, K212/R218, R114, K525, and R428, which have all been noted to be
important modification sites in glycated HSA [19,20,22,24,34].
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Some other regions that were found to have measurable levels of modification in the mildly
glycated HSA (e.g., residues 324-336, 241-257, 142-153, and 502-518) were unique to this
current study and have not been previously reported. The possible modification sites in these
regions include arginines 336, 257, 144 and 145. Although no modified peptides were found
previously in these regions of HSA when using peptide mass fingerprinting [29], this may
have been a result of the low levels of modifications seen in these regions in this current
report (as indicated by 18O-labeling) and the variety of AGEs that could be formed as these
sites. The binding of glucose or carbonyl-containing compounds at any of these sites has the
potential to alter the structure and binding properties of HSA through allosteric effects.
Furthermore, modified residues in regions 142-153 or 241-257 on HSA could potentially
alter the binding properties of HSA because these residues are located in one of the major
drug binding sites of this protein (i.e., Sudlow site I).
3.3. Peptides with high 16O/18O ratios in highly glycated HSA
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A similar examination was made of the results for the more highly glycated HSA that was
prepared after 5 weeks of incubation with 15 mmol/l glucose, as used here to represent
typical levels of glycation that might be seen in diabetes. A total of 21 peptides in this
sample were found to have a significant increase (at the 90% confidence level) in their
glycated/control index values versus the control sample. These peptides gave an increase in
the glycated/control index that ranged from 7% to 105% versus the control. The largest
amounts of modification in this sample occurred within residues 21-41, 1-10 or 42-51,
521-531, 82-93, and 146-160 of HSA. These regions gave glycated/control ratios in the
highly glycated HSA sample that were increased by 67 to 105% versus the control. Several
additional residues containing lower amounts of modification were also identified, as listed
in Table 1.
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For the highly glycated HSA, peptides that contained the N-terminus or K525 gave the
highest levels of modification. Other residues found to have significant levels of
modification included K199, R114, R218, R428 and K439 (e.g., regions 189-208, 101-119,
209-227, and 426-442). All of these residues have previously been identified as being the
most likely regions of modification on HSA when this protein is incubated with glucose
[20,40] or methylglyoxal (i.e., a reactive dicarbonyl compound that leads to AGE formation)
[22,24]. In addition, it was noted that the ranking of the major modification sites in the
highly glycated HSA sample was similar to the ranking of modification sites for the mildly
glycated HSA that was discussed in Section 3.2. For both of these samples, peptides
containing the N-terminus had the highest amount of modification, followed by peptides that
contained lysines 525, 199 and 439. Lysine 281, which was found to have a high glycated/
control index in the mildly glycated HSA sample, had a glycated/control index in the highly
glycated HSA sample that was also significantly elevated at the 90% confidence level.
3.4. Comparison of the glycated/control index for early and advanced glycation products
It was possible by combining the qualitative results from Ref. [29] with the quantitative data
from this current study to determine the modifications that were associated with the greatest
degrees of modification in the mildly and highly glycated HSA samples. For instance, in the
mildly glycated HSA there were 5 peptides with elevated glycated/control index values,
which corresponded to residues 1-10, 275-286, 87-100, and 414-428. The modifications that
occurred in these general regions of HSA have been described in Ref. [29]. Such
modifications included the formation of a dehydrate of fructosyl-lysine (FL-1H2O) at the Nterminus plus 1-alkyl-2-formyl-3,4-glycosyl-pyrrole (AFGP) at K4; the formation of FL at
K276 plus FL-1H2O at K281; the formation of FL at K281 plus Nε-carboxyethyl-lysine
(CEL) at K286 (or FL-2H2O at K281 plus pyrraline (Pyr) at K286); the production of
FL-2H2O at K93 (or CEL at K93 plus Nε-(5-hydro-5-methyl-4-imidazolon-2-yl)ornithine
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(MG-H1) at R98); and the creation of FL-1H2O at K414 plus AFGP at R428 (or AFGP at
K414 plus Nε-[5-(2,3,4-trihydroxybutyl)-5-hydro-4-imidazolon-2-yl]ornithine (3-DG-H1) at
R428).
When these modified residues in the mildly glycated HSA were ranked in order of their
glycated/control index values, the N+/K4 region had the highest amount of modification,
followed by regions containing K276/K281/K286, R98/K93, and K414/R428. A peptide that
corresponded to residues 196-205, and that was found earlier to contain FL at K199 plus 3DGH1 at R197 [28], also had a relatively high glycated/control index, but the 16O/18O ratio
for this peptide in the mildly glycated HSA sample was not significantly different from the
control result at the 90% confidence level, as stated in Section 3.2. One general observation
made from these results was that lysines (as opposed to arginines) had the highest amount of
modification in the mildly glycated sample. It was also noted that FL, or closely-related
dehydrated forms of FL, were found on these lysines. These observations are consistent with
a model in which the formation of early glycation products is favored over AGEs at the
relatively short incubation time of 2 weeks that was used to prepare the mildly glycated
sample.
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In the highly glycated HSA sample, peptides that were found to have elevated glycated/
control index values included residues 521-531, 189-208, and 426-442. These regions of the
highly glycated HSA have been determined in Ref. [29] to involve the formation of Pyr at
K524 plus Nε-(5-hydro-4-imidazolon-2-yl)ornithine (G-H1) at R521; the creation of Pyr at
K199 plus imidazolone B (IB) at R197; the formation of 3-DG-H1 or AFGP at R428; and
the production of FL-1H2O at K525. When the modified residues were ranked in order of
their glycated/control index values, the region containing K525, K524 and R521 was found
to have the highest amount of modification, followed by the regions that contained K199/
R197 and R428. A comparison of these results with those for the mildly glycated HSA
indicated that the relative importance of AGEs versus early glycation products tended to
increase with the time allowed for glycation. This finding is consistent with a model in
which there is a gradual shift from early glycation products to these products plus AGEs
over time and there is an increase in the complexity of the glycation patterns as a protein is
allowed to react with glucose over longer time intervals [1].
3.5. Changes in the glycated/control index with overall level of glycation
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Most of the modified residues that were monitored in this study had a general increase in
their glycated/control indices as the total level of glycation of HSA increased (e.g., as
occurred when HSA was incubated over longer intervals of time with glucose). The majority
of this increase occurred during the first 2 weeks of incubation between HSA and glucose.
However, the rate of this increase did vary between different regions of HSA. This behavior
is illustrated in Figure 5 for residues 1-10, 189-208, 521-531, and 426-442. As indicated
earlier, these particular residues contain the N-terminus, K199, K525, and K439/R428,
which are known to have high amounts of modification within both in vivo and in vitro
glycated HSA [19,20,24]. There were also a few peptides that gave an increase in glycationrelated modifications over 2 weeks of incubation with glucose, followed by an apparent
reduction in the levels of modification at 5 weeks of incubation (i.e., see results for residues
101-119, 154-164, 275-286, 360-372, 414-428, and 502-518 in Table 1). However, the
relative change in the modification levels between 2 and 5 weeks was generally small and/or
not statistically significant in each these cases (Note: The only possible exception was the
result for residues 360-372 in the Lys C digest, but no significant difference between the 2
and 5 week samples of glycated HSA was seen for the same peptide in the tryptic digest).
Figure 5 shows that different regions of HSA did vary in their rates of modification due to
glycation, which included related processes such as AGE formation. It was possible from
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this information to estimate the rate constants for these processes by preparing plots of the
natural logarithm of the glycated/control index versus incubation time. This type of plot
would be predicted to give a linear response if the glycation process followed a pseudo-first
order model, with the slope being related to the rate constant for the modification process. A
pseudo-first order model was sufficient in this case for use in the relative comparison of
reaction rates and was reasonable because glucose was initially present in a 24-fold mole
excess versus HSA (Note: additional time points would be needed to better determine the
order and rates of these reactions in future studies). When the data in Figure 5 were
examined according to a pseudo-first order model, the apparent rate constants for the initial
rate of glycation product formation at the N-terminus, K525, K439/R428, and K199 (or
K205) were estimated to be 2.5 × 10-5, 2.2 × 10-5, 1.1 × 10-5, and 1.1 × 10-5 min-1,
respectively, based on data acquired over incubation times of up to 2 weeks at pH 7.4 and
37°C. The rate constants obtained using data for incubation times up to 5 weeks for the same
sites were 1.3 × 10-5, 1.0 × 10-5, 0.7 × 10-5, and 0.6 × 10-5 min-1.
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The other regions on HSA that were examined by this approach gave a similar range of rate
constants for the glycation process. For instance, the modifications that occurred over 2
weeks at residues 241-257 (R257), 142-153 (R145), 61-82 (K64/K73), 154-167 (K159/
R160), and 209-227 (R218) gave pseudo-first rate order constants for these reactions of 1.3
× 10-5, 1.2 × 10-5, 1.1 × 10-5, 0.9 × 10-5, and 0.7 × 10-5 min-1. Using data for the same sites
over 5 weeks of incubation gave rate constants of 0.6 × 10-5, 0.6 × 10-5, 0.4 × 10-5, 0.3 ×
10-5 and 0.3 × 10- 5 min-1. The results obtained over 2 weeks of incubation for residues
101-119 (R114), 360-372 (K372) and 275-286 (K281) gave rate constants of 2.8 × 10-5, 2.3
× 10-5, and 1.9 × 10-5 min-1, while data over 5 weeks of incubation resulted in rate constants
of 0.8 × 10-5, 0.7 × 10-5 and 0.4 × 10-5 min-1. Although the rate of modification did vary
from one region of HSA to the next, all of the observed regions and modifications gave
pseudo-first order rate constants in the range of 10-6 to 10-5 min-1 under the incubation
conditions used in this study.
3.6 Comparison of levels of modification for in vitro versus in vivo glycated HSA
In a recent study [41], FL modifications within in vivo glycated HSA were compared and
measured in samples from 5 diabetic patients. These samples were processed by digesting
the serum samples with trypsin, passing the digests through a phenylboronic acid column
and analyzing the retained peptides by LC/MS/MS. The relative amount of each FLmodified peptide was then determined by comparing the signal to that for the FL-modified
peptide with the largest response (i.e., a peptide containing K525). Table 2 compares the
modification sites an relative ranking of these glycation sites with the results that were
obtained for the same types of modifications in this current study.
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Several peptides were found to have high levels of modification for both the in vitro
glycated HSA in this current report and the in vivo glycated HSA in Ref. [41]. Of the 18
glycation sites that were found in Ref. [41], eleven of these sites were also associated with
high and significant 16O/18O ratios in this current study. This group included all of the sites
that were found to have the greatest levels of FL formation in Ref. [41]. Of the remaining FL
sites that were examined previously [41], four were not included in the sequence coverage in
this current study but contained only small levels of FL modification in the prior report (i.e.,
K181, K351, K541, and K545). One of the remaining FL sites (K233) has been found to be
modified in prior work with in vitro glycated HSA [27]; this site may have been elevated in
this current report, although the location of this modification could not be assigned
definitively within a mass accuracy of 50 ppm. The remaining 2 sites that were monitored in
Ref. [41] (i.e., K174 and K359) were also examined in this current study but were associated
with low 16O/18O ratios. This latter result was in agreement with the relatively low levels of
FL modification that were seen for the same regions in in vivo glycated HSA [41].
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A comparison of the relative ranking of the detected FL sites in both the in vivo [41] and in
vitro studies revealed that K525 contained the largest amount of modification, followed by
lysines 335, 378, 475, and 262. A comparison of the in vivo glycated samples with the
minimally glycated HSA that was prepared in vitro using 2 weeks of incubation with
glucose revealed an even greater level of similarity that followed the relative pattern of
modification K525 > K276 > K435 > K414 > K378 > K475 > K262. This result indicates
that this in vitro glycated HSA sample was a reasonable model for the in vivo glycated HSA.
A comparison of the same in vivo glycated HSA with the glycated HSA prepared in vitro
after 5 weeks of incubation with glucose also compared well but with a slightly lower degree
of similarity (K525 > K335 > K378 > K475 > K262).
The high level of similarity between the 2 week in vitro glycated HSA sample and the in
vivo glycated HSA when looking at only FL adducts gives strong support to a model in
which FL generation is more important than AGE formation at the early stages of glycation.
A comparison of the 5 week in vitro glycated HSA and the in vivo glycated HSA further
indicates that some alterations in the relative ranking of these modification sites can then
occur as AGEs accumulate over time, coupled with the presence of some FL degradation.
These results are all consistent with the results noted earlier in Section 3.4, in which the
amounts of FL or AGE adducts were found to vary with the total extent of glycation and
time allowed for glycation.
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4. Conclusions
This paper investigated the use of 16O/18O-labeling and MALDI-TOF MS to provide
quantitative information on the modification and modification patterns that occur on in vitro
glycated HSA as a function of glycation time. The work used a glycated/control index to
correct for variations in 16O/18O ratios within the control sample throughout the structure of
HSA. This index also made it possible to compare the levels of modification from different
regions of HSA, to examine the glycation patterns of HSA under various reaction
conditions, and to estimate the rates of these modification reactions. The approach used in
this report is not limited to HSA or glycation but could also be used to examine other types
of modifications or protein systems.
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By comparing the glycated/control index values, the largest levels of modification in HSA
after 2 weeks of incubation with glucose occurred in regions 101-119, 1-10 or 42-51,
87-100, 360-372, 521-531, and 275-286. After 5 weeks of incubation, the largest amount of
modification was found on residues 21-41, 1-10 or 42-51, 521-531, 82-93, and 146-160.
Many of these regions contained residues that have been previously identified as major
glycation sites on HSA, including the N-terminus, K199, K439, and K525 [20,40]. The
glycation patterns found in this work supported a model in which FL and closely-related
early glycation products dominated at short incubation times (e.g., 2 weeks), with the
formation of AGEs also becoming important at longer incubation times (e.g., 5 weeks).
Although the rates of these modifications varied from one region of HSA to the next, these
processes were estimated to have pseudo-first order rate constants in the general range of
10-6 to 10-5 min-1.
The physiological importance of these modifications can be illustrated by comparing the
locations of the affected regions on HSA with the locations of Sudlow sites I and II (i.e., the
major drug binding sites on this protein). As shown in Figure 6, and based on data or
methods from Refs. [42,43], significant levels of modification were found to occur at or near
both Sudlow sites I and II in the mildly glycated HSA and more highly glycated HSA
samples. These modifications included those occurring at K199, K150 or K160, K275,
K281, and R209 and R257, which are all located within Sudlow site I. Modifications at or
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near Sudlow site II included those involving K378 and K439 as well as R428. The location
of these modifications explains why glycation has been observed to alter the binding of
some drugs to Sudlow sites I and/or II of HSA [23,44,45]. The changes in the levels of these
modifications and in the glycation pattern of HSA during the incubation of this protein with
glucose helps explain why the binding of drugs at these sites has been found to change in the
presence of different levels of glycation for HSA, as observed using samples comparable to
those employed in this current report [44,45]. It was further found that the relative order of
residues that formed early stage glycation products for the in vitro glycated HSA were
similar to the order that has been recently reported for in vivo glycated HSA, especially
when comparing the residues with the highest levels of modification [41]. Overall, this work
should provide a more complete picture of how glycation affects the structure of HSA and
the ability of the protein to transport and bind to drugs in individuals that are affected by
diabetes. This information, in turn, should eventually lead to better methods of treatment for
this disease as part of a regime based on personalized medicine.
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Figure 1.

Reaction scheme summarizing the various stages of glycation. The initial step (stage 1) is
reductive amination, which results in the formation of a Schiff base followed by the creation
of an Amadori product. The second stage is characterized by the oxidation of free sugars to
form glyoxal, methylglyoxal, and 3-deoxyglucosone. The final stage of this glycation is
characterized by the formation of advanced glycation end products (AGEs).
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Figure 2.

(a) Method used for labeling peptides with 18O. HSA is reconstituted in buffer that is
enriched with 16O-labeled water and glycated HSA is reconstituted in buffer that was
enriched with 18O-labeled water. The HSA and glycated HSA samples are then digested in
an identical fashion. The resulting peptide solution is then mixed in a 50:50 (v/v) fashion.
(b) Mass spectra are collected for the 16O, 18O, and mixed oxygen labeled digests (left to
right), and the relative abundances obtained from these spectra are used to determine
the 16O/18O ratios. The solid bars represent the contribution of 16O and the hashed bars
show the contribution of 18O to each m/z value in an isotope cluster.
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Figure 3.

The usable sequence coverages for the samples examined in this study. The sequence
coverage for the control HSA and five week glycated HSA sample is shown in bold and
caps (Note: The coverages for these two samples were identical). The sequence coverage for
the HSA-2 sample is shown by an underline. The lower case letters represents the remainder
of the sequence in HSA, for which no 16O/18O ratio determinations were made.
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Figure 4.

Mass spectra showing the change in 16O/18O ratio for a peptide from residues 521-531 of
HSA as the level of glycation for HSA was increased in going from (a) the control digest to
(b) glycated HSA prepared after two weeks of incubation with glucose. An even larger
change was seen in this case when using the glycated HSA that was prepared after five
weeks of incubation with glucose (data not shown). The region of HSA that was examined
in this case contains K525, which is known to be a major glycation site on HSA [20].
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Figure 5.

Plot of the mean glycated/control index values versus time for the most commonly identified
glycation sites on HSA [19,20,24]. These results are for residues 1-10 (○), 521-531 (□),
189-208 (Δ), and 426-442 (◇). Previous studies have indicated that the N-terminus, R521/
K525, K199/K205 (the K205 being identified by tandem MS), and R428/K439 were
modified to form mixtures of FL and AGEs [29]. The precision of the mean values shown in
this plot are provided in Table 1.
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Figure 6.
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Locations of regions on HSA that gave high values for the glycated/control index and that
occurred near Sudlow sites I and II. This image was generated using the crystal structure of
HSA [41] and Visual Molecular Dynamics software [42]. This structure includes
information on the region of HSA that is being modified, the specific residues that were
most likely modified in this region [34], and the glycated/control index values for this
regions in the glycated HSA samples after two or five weeks of incubation.
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1.92 (± 0.20), 3

1.37 (± 0.33), 2

1.66 (± 0.10), 9

1.68 (± 0.00), 3

1.31 (± 0.07), 6

2.38 (± 0.56), 3

1.85 (± 0.20), 3

1.59 (± 0.05), 9

1.11 (± 0.12), 6

1.69 (± 0.19), 6

1.10 (± 0.20), 3

2.43 (± 0.15), 6

2.33 (± 0.27), 6

2.02 (± 0.24), 6

2.01 (± 0.41), 6

2.07 (± 0.54), 6

1.36 (± 0.31), 6

1.48 (± 0.13), 3

0.46 (± 0.05), 6

1.19 (± 0.16), 8

1.57 (± 0.33), 6

2.55 (± 0.25), 3

1.59 (± 0.18), 9

1.30 (± 0.06), 9

1.94 (± 0.14), 9

2 Week Sample

0.84 (± 0.06), 6

1.43 (± 0.39), 3

3.50 (± 0.42), 3

0.75 (± 0.14), 3

1.65 (± 0.08), 9

1.95 (± 0.17), 6

1.45 (± 0.06), 6

2.47 (± 0.24), 6

2.59 (± 0.43), 3

1.86 (± 0.13), 6

1.33 (± 0.24), 3

1.38 (± 0.08), 6

1.32 (± 0.23), 3

3.05 (± 0.16), 6

1.86 (± 0.08), 6

1.49 (± 0.33), 6

2.43 (± 0.26), 7

2.42 (± 0.37), 6

1.89 (± 0.38), 6

0.95 (± 0.13), 6

1.03 (± 0.09), 5

1.34 (± 0.13), 6

3.20 (± 0.69), 6

2.02 (± 0.65), 6

1.55 (± 0.07), 9

1.53 (± 0.08), 9

2.02 (± 0.14), 9

5 Week Sample

Ratio, Number of Replicates (n)

Control Sample

16O/18O

0.88 (± 0.08)

0.68 (± 0.26)

1.12 (± 0.19)

0.79 (± 0.27)

1.31 (± 0.12)

1.17 (± 0.11)

0.90 (± 0.09)

1.61 (± 0.46)

1.19 (± 0.25)

1.09 (± 0.10)

0.92 (± 0.26)

1.29 (± 0.18)

0.72 (± 0.19)

1.31 (± 0.11)

1.60 (± 0.29)

1.47 (± 0.44)

1.00 (± 0.25)

1.14 (± 0.36)

1.24 (± 0.39)

1.22 (± 0.24)

0.64 (± 0.11)

0.76 (± 0.17)

0.79 (± 0.27)

1.53 (± 0.58)

1.19 (± 0.19)

0.86 (± 0.09)

1.17 (± 0.13)

2 Week Sample

0.91 (± 0.08)

0.79 (± 0.30)

2.05 (± 0.35)

0.43 (± 0.15)

1.30 (± 0.12)

1.36 (± 0.13)

0.99 (± 0.09)

1.67 (± 0.48)

1.67 (± 0.34)

1.27 (± 0.12)

1.10 (± 0.32)

1.05 (± 0.15)

0.87 (± 0.23)

1.65 (± 0.13)

1.27 (± 0.23)

1.09 (± 0.33)

1.21 (± 0.30)

1.34 (± 0.43)

1.72 (± 0.55)

0.79 (± 0.15)

1.43 (± 0.24)

0.86 (± 0.19)

1.61 (± 0.55)

1.21 (± 0.46)

1.16 (± 0.18)

1.01 (± 0.10)

1.22 (± 0.13)

5 Week Sample

Glycated/Control Index

Results based on 16O/18O measurements for glycated HSA samples after two or five weeks of incubation in 15 mM glucosea
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Lys-C

Glu-C

6
-1
4
-5

854.46
973.52
1149.62
1342.63

-7

-4

2578.26

1529.86

-42

2348.09

-8

-19

2232.21

-10

-11

2194.15

1443.63

-38

2085.99

1371.55

-8

1955.98

-3

5-12

-1

1945.86

1352.76

206-212

0

213-225

263-274

163-174

403-413

546-557

1-10

61-82

101-119

209-227

189-208

377-393

426-442

502-518

451-465

-4

1801.92

87-100

154-167

466-479

480-492

506-518

142-153

521-531

7-17

496-505

369-376

287-313

115-137

445-466

115-136

Residues

1737.69

-5
-22

2

1519.79

1704.91

4

1313.80

1680.80

7

1300.67

36

-6

1197.57

-16

3

1031.45

1548.77

-10

2974.31

1541.75

-1
25

2778.43

15

2674.31

Error (ppm)

2650.30

NIH-PA Author Manuscript
Mass (u)

1.27 (± 0.03), 6

1.37 (± 0.18), 7

1.44 (± 0.18), 6

1.29 (± 0.05), 9

1.48 (± 0.17), 3

1.00 (± 0.13), 3

1.13 (± 0.18), 3

0.51 (± 0.31), 3

0.68 (± 0.01), 3

0.99 (± 0.02), 6

1.12 (± 0.04), 6

0.93 (± 0.05), 5

1.22 (± 0.10), 6

1.15 (± 0.04), 5

1.16 (± 0.02), 3

0.49, 1

1.19 (± 0.14), 5

1.63 (± 0.08), 6

1.15 (± 0.10), 3

1.29 (± 0.07), 9

1.42 (± 0.23), 5

1.40 (± 0.09), 12

1.15 (± 0.13), 5

1.57 (± 0.18), 6

0.96 (± 0.34), 6

1.92 (± 0.27), 6

1.05 (± 0.04), 2

1.01 (± 0.01), 3

0.99 (± 0.03), 3

1.21 (± 0.02), 3

Control Sample

1.26 (± 0.03), 6

1.36 (± 0.05), 6

1.43 (± 0.14), 6

1.09 (± 0.08), 9

1.10 (± 0.12), 3

1.64 (± 0.31), 6

0.93 (± 0.04), 3

1.40 (± 0.33), 3

0.84 (± 0.03), 3

1.75 (± 0.45), 6

1.30 (± 0.09), 6

1.16 (± 0.40), 6

1.46 (± 0.11), 6

1.38 (± 0.05), 6

1.48 (± 0.04), 3

Not detected

1.76 (± 0.29), 6

1.98 (± 0.03), 6

1.33 (± 0.22), 6

1.40 (± 0.05), 9

1.41 (± 0.39), 3

1.80 (± 0.23), 12

1.80 (± 0.46), 6

2.00 (± 0.41), 6

0.46 (± 0.05), 2

1.44 (± 0.46), 3

Not detected

0.92 (± 0.02), 3

0.78 (± 0.05), 3

1.24 (± 0.07), 3

2 Week Sample

1.21 (± 0.03), 6

1.28 (± 0.11), 6

1.23 (± 0.09), 6

1.32 (± 0.22), 12

1.07 (± 0.09), 3

1.99 (± 0.37), 3

1.04 (± 0.07), 5

1.76 (± 0.50), 5

0.80 (± 0.06), 6

1.21 (± 0.05), 3

1.24 (± 0.03), 6

1.29 (± 0.22), 6

1.43 (± 0.14), 6

1.46 (± 0.04), 6

1.19 (± 0.20), 3

2.23, 1

1.70 (± 0.20), 6

1.84 (± 0.13), 7

1.40 (± 0.29), 5

1.36 (± 0.11), 7

1.66 (± 0.09), 3

1.76 (± 0.06), 9

2.00 (± 0.46), 3

1.87 (± 0.24), 6

1.20 (± 0.27), 3

1.43 (± 0.21), 6

1.21 (± 0.49), 2

1.09 (± 0.05), 3

0.93 (± 0.21), 3

1.11 (± 0.01), 3

5 Week Sample

Ratio, Number of Replicates (n)

0.99 (± 0.04)

0.99 (± 0.16)

0.99 (± 0.18)

0.84 (± 0.16)

0.74 (± 0.13)

1.64 (± 0.49)

0.82 (± 0.15)

2.75 (± 1.96)

1.24 (± 0.10)

1.77 (± 0.46)

1.16 (± 0.10)

1.25 (± 0.49)

1.20 (± 0.18)

1.20 (± 0.07)

1.28 (± 0.21)

Not detected

1.48 (± 0.34)

1.21 (± 0.11)

1.16 (± 0.33)

1.09 (± 0.11)

0.99 (± 0.33)

1.29 (± 0.19)

1.57 (± 0.57)

1.27 (± 0.34)

0.48 (± 0.21)

0.75 (± 0.28)

Not detected

0.91 (± 0.05)

0.79 (± 0.19)

1.02 (± 0.06)

2 Week Sample

0.95 (± 0.04)

0.93 (± 0.15)

0.85 (± 0.15)

1.02 (± 0.19)

0.72 (± 0.13)

1.99 (± 0.59)

0.92 (± 0.17)

3.45 (± 2.47)

1.18 (± 0.09)

1.22 (± 0.32)

1.11 (± 0.09)

1.39 (± 0.54)

1.17 (± 0.18)

1.27 (± 0.07)

1.03 (± 0.17)

4.55

1.43 (± 0.33)

1.13 (± 0.10)

1.22 (± 0.34)

1.05 (± 0.11)

1.17 (± 0.38)

1.26 (± 0.18)

1.74 (± 0.63)

1.19 (± 0.32)

1.25 (± 0.54)

0.74 (± 0.28)

1.15 (± 0.47)

1.08 (± 0.05)

0.94 (± 0.22)

0.92 (± 0.05)

5 Week Sample

Glycated/Control Index

NIH-PA Author Manuscript

16O/18O
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-4
-9
-7
-17
-22
-17
-16
-20
-17
-11
-11
-6

1657.74

1714.79

1924.05

2045.05

2052.15

2259.99

2348.99

2490.24

2585.09

2674.29

2807.45

138-159

445-466

241-262

21-41

74-93

21-41

414-432

373-389

415-432

94-106

390-402

360-372

Residues

0.84 (± 0.01), 3

0.88 (± 0.02), 3

0.93 (± 0.07), 9

0.79 (± 0.06), 3

0.83 (± 0.01), 3

1.53 (± 0.23), 6

1.26 (± 0.06), 6

1.28 (± 0.03), 3

0.73 (± 0.13), 3

1.17 (± 0.02), 9

1.54 (± 0.24), 5

1.31 (± 0.04), 6

Control Sample

0.84 (± 0.04), 3

0.86 (± 0.05), 3

0.88 (± 0.02), 6

0.65 (± 0.07), 3

0.80 (± 0.10), 6

Not detected

1.01 (± 0.06), 6

1.17 (± 0.03), 3

0.52 (± 0.01), 3

1.25 (± 0.01), 9

1.48 (± 0.29), 6

1.71 (± 0.05), 6

2 Week Sample

0.75 (± 0.02), 3

0.70 (± 0.05), 3

0.92 (± 0.02), 3

0.98 (± 0.08), 3

0.95 (± 0.10), 6

Not detected

1.15 (± 0.03), 6

1.30 (± 0.05), 3

0.39 (± 0.07), 3

1.17 (± 0.03), 6

1.34 (± 0.25), 5

1.40 (± 0.02), 6

5 Week Sample

1.00 (± 0.05)

0.98 (± 0.10)

0.95 (± 0.08)

0.82 (± 0.12)

0.96 (± 0.16)

Not detected

0.80 (± 0.07)

0.91 (± 0.05)

0.71 (± 0.18)

1.07 (± 0.04)

0.96 (± 0.30)

1.31 (± 0.06)

2 Week Sample

0.89 (± 0.05)

0.80 (± 0.08)

0.99 (± 0.08)

1.24 (± 0.19)

1.14 (± 0.19)

Not detected

0.91 (± 0.08)

1.02 (± 0.05)

0.53 (± 0.13)

1.00 (± 0.03)

0.87 (± 0.27)

1.07 (± 0.05)

5 Week Sample

Glycated/Control Index

The values shown in parentheses represent ± 1 standard error of the mean. The values in bold represent cases for which the calculated 16O/18O ratio for the glycated sample was higher than the 16O/18O
ratio for the control sample at the 90% confidence level.

a

Error (ppm)

1552.59

NIH-PA Author Manuscript

Mass (u)

NIH-PA Author Manuscript
Ratio, Number of Replicates (n)

NIH-PA Author Manuscript
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NIH-PA Author Manuscript

NIH-PA Author Manuscript
K64

1680.80

2045.10

1704.91

2578.26

1639.94

1623.80

1546.80

1313.80

1149.62

Glu-C

Trypsin

Glu-C

Glu-C

Trypsin

Trypsin

Trypsin

Glu-C

Lys-C

1-10 or K51c

K525 or K524/K525

K276

K335

K414

K378

K475

K262

1.04 (11)

1.00 (10)

0.94 (9)

0.83 (8)

0.82 (7)

0.79 (6)

0.77 (5)

0.75 (4)

0.74 (3)

0.61 (2)

0.50 (1)

1.14 (11)

1.00 (10)

0.63 (3)

0.95 (9)

0.60 (2)

0.68 (5)

0.65 (4)

0.78 (7)

0.70 (6)

0.57 (1)

0.93 (8)

5 Week Sample

3.3 (2)

100 (11) or 13.5 (7)

46.7 (9)

27.5 (8)

11.5 (6)

7.4 (3)

59.9 (10)

10.8 (5)

7.6 (4)

1.2 (1)

3.3 (2)

In vivo HSA [41]

Change Relative to K525
2 Week Sample

c
This particular 16O/18O ratio could correspond to either residues 1-10 or 42-51. These peptides could not be differentiated at the 50 ppm level of mass accuracy that was used as the cut-off in this report.

The amino acid sequence for precursor HSA was used for peptide mapping in Ref. [41]. The listed sites were converted to those for the same amino acids in the sequence for mature HSA, as used in this
current study, for the sake of consistency in the comparison.

b

The in vivo results are based on data from Ref. [41]. The values for the in vitro samples were determined by comparing the glycated/control index for the indicated peptide to the same index for a peptide
containing K525. The relative ranking is given in parenthesis and is in increasing order from 1-13. The values in italics represent residues that have a similar modification rank in all three samples. Values in
bold represent residues that have a similar rank in the two week in vitro glycated HSA and in vivo glycated HSA. The underlined values represent residues that are similarly ranked in the five week in vitro
glycated HSA and in vivo glycated HSA.

a

K162

2585.09

Lys-C

1-10 or K51c

1149.60

Trypsin

Residueb

Mass (u)

Digest

Comparison of quantitative data obtained for in vitro glycated HSA and for in vivo glycated HSAa
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